following an abbreviated submission:
dolutegravir / lamivudine (Dovato®) is accepted for use within NHSScotland.
Indication under review: for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
In patients for whom this two-drug combination regimen is appropriate dolutegravir / lamivudine (Dovato®) offers a single tablet at no additional cost compared with the two individual components.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of dolutegravir / lamivudine. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice366KB (PDF)
- Medicine name:
- dolutegravir lamivudine (Dovato)
- SMC ID:
Treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Submission type
- Date advice published:
- 09 September 2019